000 02042cam  2200301za 4500
0019.847765
003CaOODSP
00520221107153520
007cr |||||||||||
008171124s2018    onc     o    f000 0 eng d
020 |a9780660240114|z9780660240121
040 |aCaOODSP|beng
043 |an-cn---
0861 |aNR16-182/2017E-PDF
1102 |aNational Research Council Canada.
24510|aExtending in vivo half-life of therapeutic proteins (L-11944) |h[electronic resource].
260 |a[Ottawa] : |bNational Research Council Canada, |c[2018]
300 |a[1] p.
500 |aIssued also in French under title: Accroître la demi-vie in vivo des protéines thérapeutiques (L-11944).
500 |aCaption title.
500 |a"December 2017."
520 |a“Post-translational modifications of therapeutic proteins are commonly made to improve their circulating half-life, thereby enhancing their efficiency. Numerous strategies have been employed towards this end, including covalent modification, such as through PEGylation, the chemical addition of chains of polyethylene glycol (PEG) to therapeutic proteins. However, PEGylation relies on chemical conjugation of PEG chains to free amino groups or engineered cysteine residues on the protein, which can lead to heterogeneously-modified proteins whose activity can be adversely affected. To address this, the NRC has developed a site-specific, two-step in vitro modification process whereby polysialic acid (PSA) is enzymatically added to existing glycans, resulting in proteins with greater stability, solubility and circulating half-life”--Highlights.
530 |aIssued also in print format.
693 4|aRecombinant proteins
693 4|aProtein engineering
77508|tAccroître la demi-vie in vivo des protéines thérapeutiques (L-11944) |w(CaOODSP)9.847777
7760#|tExtending in vivo half-life of therapeutic proteins |w(CaOODSP)9.847766
85640|qPDF|s122 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-182-2017-eng.pdf